S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Seattle Genetics and Takeda Report Phase 3 AETHERA Clinical Trial Data from ADCETRIS® (Brentuximab Vedotin) in Post-Transplant Hodgkin Lymphoma Patients at Risk of Relapse at ASH Annual Meeting (2014/12/6)|
|Accenture Supports ‘Pay for Success’ Initiatives for U.S. State and Local Governments (2015/1/21)|
|Pfizer Initiates Phase 2 Study of PF-06252616 in Duchenne Muscular Dystrophy (2014/12/17)|
|Bank of America and Social Finance Inc. Study Reveals Potential to Expand Services for Military Veterans Through Innovative Pay for Success Programs (2015/2/18)|
|Dominion Diamond Corporation Announces Jay Project Pre-Feasibility Study Results (2015/1/27)|
|CytRx Announces Overall Survival Results from Its Global Phase 2b Clinical Trial of Aldoxorubicin in Soft Tissue Sarcoma (2015/1/22)|
|Seattle Genetics Submits Supplemental BLA to FDA for Phase 3 AETHERA Trial of ADCETRIS® (Brentuximab Vedotin) in Post-Transplant Hodgkin Lymphoma Patients at High Risk of Relapse (2015/2/18)|
|Phase 3 Results Published in The New England Journal of Medicine Show Superiority of Pfizer’s XALKORI® (crizotinib) Compared to Platinum-Based Chemotherapy in Previously Untreated Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (2014/12/3)|
|Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors (2014/12/16)|
|Gilead Presents Follow-up Data from Zydelig Registrational Studies in Patients with Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma (2014/12/8)|
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Access Your Portfolio Anytime, Anywhere via Your Mobile Device|
|P||Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)|
|P||Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)|
|P||Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)|
|P||Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters|
|P||Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.
Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.
Click above to view more mutual fund data and stats for pf-f - Property Perfect PLC Shs Foreign Registered.